In the FLAURA2 [21], first-line treatment with osimertinib plus chemotherapy led to significantly longer progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC (HR, 0.62; 95% CI 0.49 to 0.79). This evidence concerns the gene EGFR and non-small cell lung carcinoma.